Literature DB >> 18208948

Labour pains.

Michael Andrew Duncan.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18208948      PMCID： PMC2329899     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  7 in total

Review 1.  Single-dose intrathecal analgesia to control labour pain: is it a useful alternative to epidural analgesia?

Authors:  R G Minty; Len Kelly; Alana Minty; D C Hammett
Journal:  Can Fam Physician       Date:  2007-03       Impact factor: 3.275

Review 2.  The use of neuraxial adjuvant drugs (neostigmine, clonidine) in obstetrics.

Authors:  Fabienne Roelants
Journal:  Curr Opin Anaesthesiol       Date:  2006-06       Impact factor: 2.706

3.  Analgesic efficacy of two doses of intrathecal midazolam with bupivacaine in patients undergoing cesarean delivery.

Authors:  Smita Prakash; Nandita Joshi; Anoop R Gogia; Sunil Prakash; Rajvir Singh
Journal:  Reg Anesth Pain Med       Date:  2006 May-Jun       Impact factor: 6.288

4.  Intrathecal midazolam combined with low-dose bupivacaine improves postoperative recovery in diabetic mellitus patients undergoing foot debridement.

Authors:  Yu-Wha Wu; Jieh-Min Shiau; Chao-Chun Hong; Chih-Peng Hung; Hsiao-Feng Lu; Chia-Chih Tseng
Journal:  Acta Anaesthesiol Taiwan       Date:  2005-09

5.  Intrathecal midazolam II: combination with intrathecal fentanyl for labor pain.

Authors:  Adam P Tucker; Joseph Mezzatesta; Raymond Nadeson; Colin S Goodchild
Journal:  Anesth Analg       Date:  2004-06       Impact factor: 5.108

Review 6.  The use of intrathecal midazolam in humans: a case study of process.

Authors:  Tony L Yaksh; Jeffrey W Allen
Journal:  Anesth Analg       Date:  2004-06       Impact factor: 5.108

7.  Intrathecal midazolam I: a cohort study investigating safety.

Authors:  Adam P Tucker; Cindy Lai; Raymond Nadeson; Colin S Goodchild
Journal:  Anesth Analg       Date:  2004-06       Impact factor: 5.108
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.